Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Intrathecal baclofen is a formulation of the muscle relaxant and antispastic agent baclofen, administered directly into the cerebrospinal fluid via an implanted pump system. This delivery method is used for the management of severe spasticity of cerebral or spinal origin in patients who are unresponsive to oral therapy or experience intolerable side effects from oral administration. Baclofen acts primarily as an agonist at gamma-aminobutyric acid type B (GABA-B) receptors in the central nervous system, leading to inhibition of both mono- and polysynaptic reflexes at the spinal cord level, resulting in reduced muscle tone and spasticity. The intrathecal route allows for effective concentrations at the site of action with much lower systemic exposure compared to oral dosing, minimizing systemic side effects[1][2][5][9]. Indications include severe spasticity due to multiple sclerosis, cerebral palsy, traumatic brain injury (after one year), or spinal cord injury[1][5][9].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on intrathecal baclofen.